Biotech | October 13, 2021
Roche’s 8-year safety data of Ocrevus shows reduced risk in multiple sclerosis patients
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
This expansion will support the global operations network and help meet global demand for mammalian development services that support Lonza’s manufacturing sites
Harvard Medical School will deliver the first customized program, ‘Accelerate’, to create the next generation of leading experts in clinical development and medical affairs
Through this initiative, the Centre for Trauma will create curriculums and facilitate trauma-related courses for healthcare professionals at both urban and grassroot levels
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE)
Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
A growing number of studies have shown the benefit of a third dose of Covid-19 vaccine in immunocompromised subjects
The rates for over 400 procedures were revised
The transaction is anticipated to close in the first quarter of 2022
Subscribe To Our Newsletter & Stay Updated
